News Articles

Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc. SAINT-PREX, Switzerland & ROSEVILLE, Minn. -Thursday, April 5th 2018  

Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product CDI is one of the most common healthcare-associated infections in...

Nocturia: the most common cause of a poor night’s sleep, say experts on World Sleep Day SAINT-PREX, Switzerland -Friday, March 16th 2018  

Nocturia, the need to wake to urinate more than once in the night, is the most common cause of sleep disruption in adults of all ages.1,2 The condition is associated with loss of deep sleep, disruption of daytime functioning and reduced productivity and alertness.3,4,5 In rare cases,...

Ferring Announces Positive Outcome of European Decentralised Procedure (DCP) for Testavan®, a Treatment... SAINT PREX, Switzerland -Thursday, March 15th 2018

Testavan® expands treatment options for men with hypogonadism, a condition which causes low levels of testosterone and which may adversely affect quality of life and sexual function1-3 Men treated with Testavan achieved normalised testosterone levels after three months, with improvements...

March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London WHITE PLAINS, N.Y. & SAINT-PREX, Switzerland -Wednesday, March 7th 2018  

(BUSINESS WIRE) -- March of Dimes and Ferring Pharmaceuticals today announced that March of Dimes has selected Imperial College London as the first European partner to join its network of Prematurity Research Centers working to find the unknown causes of preterm birth and new ways to prevent...

Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage SAINT-PREX, Switzerland, & KENILWORTH, N.J. -Thursday, February 22nd 2018  

Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the leading direct cause of maternal mortality worldwide1 The CHAMPION trial is assessing the effectiveness and safety of heat-stable carbetocin vs. oxytocin, the current standard of care, for preventing PPH after...

Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland SAINT-PREX, Switzerland -Wednesday, February 14th 2018

(BUSINESS WIRE) -- Ferring Pharmaceuticals announced today that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland. Over the next three years, Ferring...

Ferring Announces Recipients of Innovation Grants Program 2017-2018 SAINT-PREX, Switzerland -Friday, January 26th 2018

(BUSINESS WIRE)-- Ferring Pharmaceuticals today announced the recipients of the 2017-2018 Innovation Grants Program, an annual initiative of the Ferring Research Institute (FRI) based in San Diego. This global program supports research in the fields of reproductive medicine and women’s health,...

Ferring enters into worldwide OmniAb® platform license agreement with Ligand SAINT-PREX, Switzerland -Monday, January 22nd 2018

Ferring Pharmaceuticals will use Ligand’s OmniAb® platform to discover new human monoclonal antibodies Through this platform, Ferring aims to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology Agreement...

Ferring and the Chinese Academy of Sciences Collaborate to Advance Research in Reproductive Medicine SAINT-PREX, Switzerland -Thursday, January 11th 2018 [ar]  

(BUSINESS WIRE) -- Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) today announced a long-term collaboration to advance basic and translational research in reproductive medicine through the development of novel product candidates and therapeutic strategies. As part of the...

Ferring Receives Swiss Approval For Rekovelle®, The First Personalised Fertility Treatment Using an... SAINT-PREX, Switzerland -Monday, November 27th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in...

Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector... SAINT-PREX, Switzerland -Tuesday, October 10th 2017

Ferring enters agreement with Antares Pharma Inc. for worldwide rights to ZomaJet™ needle-free injector device ZomaJet is used to deliver Ferring’s Zomacton® (somatropin), indicated to treat Growth Hormone Deficiency in children and Turner Syndrome in girls ZomaJet helps increase...

Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer SAINT-PREX, Switzerland -Tuesday, October 3rd 2017

(BUSINESS WIRE) -- Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately. He will be responsible for Global Medical Affairs, Quality Assurance and Pharmacovigilance. In addition, he will...

Ferring Appoints Lars Peter Brunse to Executive Board SAINT-PREX, Switzerland -Monday, July 3rd 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective immediately. Lars Peter Brunse joined Ferring as Associate Director Technical...

Ferring Appoints Aaron Graff to Executive Board SAINT-PREX, Switzerland -Thursday, June 1st 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective immediately. Aaron Graff joined Ferring in 2002 as Vice President Global...

World Bedwetting Day Steering Committee: New global guidelines call for more effective treatment for bedwetting, a... SAINT-PREX, Switzerland -Tuesday, May 30th 2017 [ar]  

Bedwetting affects 1 in 15 seven year olds1 Boys are twice as likely to suffer as girls and the risk is 44% if one parent wet the bed and 77% if both did, suggesting a genetic link2 Bedwetting has a serious impact on self-esteem, emotional well-being, functioning and school/work...

Ferring Announces Exclusive Agreement with Alrise Biosystems for the Development of an Injectable, Controlled-Release... SAINT-PREX, Switzerland -Monday, April 10th 2017

(BUSINESS WIRE) -- Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise’s ImSus® Technology Platform for the development of an injectable, controlled-release...

Ferring Highlights Progress on Social and Environmental Goals in Corporate Social Responsibility (CSR) Review 2015-2016 ... SAINT-PREX, Switzerland -Thursday, April 6th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals releases its second Corporate Social Responsibility (CSR) review, highlighting progress on social and environmental goals in 2015 and 2016 across four key pillars for focus and activity: People, Business Ethics, Environment and Community. "We have...

Ferring Appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer SAINT-PREX, Switzerland -Monday, April 3rd 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective 1st July 2017. Moorhead succeeds Peter Wilden, who joined Ferring 25 years ago and was one of the original members of the Group...

Ferring Pharmaceuticals: Waking up to Go to the Toilet is the Number One Cause of a Poor Night’s Sleep, Say... SAINT PREX, Switzerland -Friday, March 17th 2017 [ar] [fr]

Nocturia, the need to wake up and urinate more than once at night, disturbs the sleep of 1 in 3 adults over the age of 30 and two thirds of adults over the age of 651 Up to 80% of people who complain of a disturbed night’s sleep report that nocturia is the main reason they wake in the...

Ferring collaborates with ICF on development of a potential new treatment for anal fissures with a focus on improving... SAINT-PREX, Switzerland -Wednesday, March 15th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals and Brazil-based Instituto de Ciências Farmacêuticas (ICF) today announced a research collaboration aimed at developing a mucoadhesive rectal delivery system to treat anal fissures and to improve quality of care for patients with inflammatory bowel...

Results 1-20 of 28